Full Professor of Cell Biology, Universitat Politècnica de València. Head Molecular Oncology Lab -FIHGUV. Vice President International Society of Liquid Biopsy
🩸That's a wrap for #ISLB2026! 🧬
Lots of science, new technological developments, and the best networking in Madrid.
From plenary sessions to fun photocalls, this is what community looks like! 📸
See you next year in Bologna
@isliquidbiopsy@ExcelenciaOnco1@UmbertoMalapel1
Even during the breaks at #ISLB2026, there's always time for a fun photocall! 📸
So proud to be here in Madrid with my Molecular Oncology Lab team from @eom.
Great science, great teamwork 🩸🩸 @eOM_Valencia@fihguv@isliquidbiopsy
🗣️ El cáncer de pulmón también es investigación, avances y nuevas oportunidades.
⭕¿Y si cambiamos la pregunta?
👉 Nuestros especialistas ponen el foco en los retos científicos y sanitarios que pueden cambiar su futuro.
🙌 Es hora de hablar de lo que realmente importa.
#CáncerDePulmón#CambiemosLaPregunta#DíaMundialDelCáncerDePulmón
Packed and ready! 🧳
On my way to Madrid for the ISLB Congress!
So excited to reconnect with the liquid biopsy community, share what we've been working on, and learn from everyone there.
See you soon, Madrid! 🇪🇸 #LiquidBiopsy@isliquidbiopsy@ExcelenciaOnco1@UmbertoMalapel1
🏥El @HGUVALENCIA pone en marcha #ERASTOR, un programa para mejorar la recuperación de los pacientes sometidos a cirugía torácica
🫁 Optimiza todo el proceso asistencial: desde la preparación del paciente antes de la operación hasta su recuperación
📎 breu.gva.es/b/9uP6np
See You in Madrid for ISLB 2026!
The countdown is almost over! From 7–9 November 2026, the global liquid biopsy community will come together in Madrid, Spain, for the ISLB 2026 Annual Congress.
This year marks a special milestone as we celebrate 10 years of ISLB, bringing together leading researchers, clinicians, and industry experts to share groundbreaking discoveries, exchange knowledge, and shape the future of liquid biopsy.
We look forward to welcoming you for three days of scientific innovation, meaningful discussions, and valuable connections.
✈️ Safe travels to everyone joining us. See you in Madrid!
#ISLB2026#LiquidBiopsy#ISLB10Years#CancerResearch#PrecisionMedicine#Madrid2026
See which technologies are shaping the next generation of liquid biopsy at ISLB 2026.
The technical session “Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches” will spotlight innovative methods expanding what can be detected, characterised and understood through liquid biopsy.
Topics will include:
• Extracellular vesicles as functional biomarkers
• Microfluidic isolation and functional analysis of circulating tumour cells
• Multimodal liquid biopsy in small cell lung cancer
• Diagnostic leukapheresis and molecular characterisation of CTCs
• Multi-omic approaches to blood-based cancer biomarkers
Chaired by Dr María José Serrano and Prof Paola Gazzaniga, the session will feature contributions from:
• Dr Kenneth Witwer
• Assoc. Prof. Han Wei Hou
• Dr Alfonso Calvo
• Prof Nikolas Stoecklein
• Prof Megan Hitchins
• Dr Mattia Boeri
Join us in Madrid on Saturday, 7 November, as researchers explore the technologies and emerging approaches helping define the future of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info#ISLB2026#LiquidBiopsy#CTCs#ExtracellularVesicles#CancerResearch#PrecisionOncology
Advancing liquid biopsy requires more than promising technology — it requires collaboration, robust evidence and meaningful exchange between research and clinical practice.
Researchers, clinicians and industry experts will come together in Madrid to examine the latest evidence, share perspectives and explore how liquid biopsy can continue to support more informed approaches to cancer care.
Be part of the discussions shaping the next chapter of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info#ISLB2026#LiquidBiopsy#PrecisionOncology#CancerResearch#Oncology#CancerCare
🧬 ISLB Global Molecular Tumor Board: Breast Cancer
Thank you to everyone who joined today’s ISLB Global Molecular Tumor Board – Breast Cancer, part of the ISLB Education Series.
The interactive session explored the evolving role of liquid biopsy and ctDNA in breast cancer, with a particular focus on molecular residual disease (MRD) in early triple-negative breast cancer, ctDNA dynamics around neoadjuvant therapy and surgery, and the potential future role of molecular monitoring in treatment escalation and de-escalation.
A key discussion centered on an increasingly important question:
Can ctDNA move from predicting recurrence to actually guiding treatment decisions in early breast cancer?
Many thanks to our moderators Mark Basik and Adriana Aguilar, presenter Mark Basik, and invited panelists Cristiano Ferrario, @AlexandrePCheng , @jvburnier , and Parvaneh Fallah for an engaging and clinically relevant discussion.
On behalf of the ISLB Education Committee, coordinated by @BrunaPellini and @JordiRemon , thank you to our faculty and participants for making this another highly interactive Global MTB session.
🌍 Advancing molecular diagnostics through global discussion, education, and collaboration.
#ISLB#LiquidBiopsy#BreastCancer#ctDNA#MRD#TNBC#PrecisionOncology#MolecularTumorBoard@UmbertoMalapel1@ElJanLe@drgandara@MJOSESERRANO19@ChristianRolfo@RobertoBoreaMD@ErulEnes@ReduzziCarol@ddemiguelperez@PasqualePisapia@BenBleibergMD@Al3ssandroRusso@ESaldanhaMD@eleonora_nicolo@DrMirallas@LuisRaezMD@DrYukselUrun
#ISLB2026 If you are working in liquid biopsy or you just want to learn about how it is evolving into so many standards of care, come join us in Madrid. Unique multidisciplinary stakeholder workshop is a highlight. Nothing like it in the world. @isliquidbiopsy@UmbertoMalapel1